BioSpace News Archive

Median Technologies (FR0011049824, ALMDT, PEA/SME eligible) (Paris:ALMDT), will be participating in the TD Cowen’s 44th Annual Health Care Conference, taking place on March 4 – 6 ,2024, at the Boston Marriott Copley Place in Boston, MA, USA.

Alvotech, a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced that Christina Siniscalchi will join its corporate leadership team as interim Chief Quality Officer.

4D Molecular Therapeutics, a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, reported full year 2023 financial results and provided operational highlights.

PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that the first patient was dosed in its randomized first-line Phase 2 trial, CRDF-004, for patients with RAS-mutated metastatic colorectal cancer (mCRC).

ProKidney Corp., a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease, announced that senior members of the management team will be participating in the Jefferies Biotech on the Bay Summit being held in Miami on March 12 – 13, 2024.

Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a corporate update.

Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today reported financial results and business highlights for the fourth quarter and year ended December 31, 2023.

Organogenesis Holdings Inc. reported financial results for the fourth quarter and the year ended December 31, 2023.

Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases, announced today its financial results for the fourth quarter and full year ended December 31, 2023 and provided a corporate update.